Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Reported side effects Mild headache or fatigue typically transient during initial use Mild gastrointestinal discomfort reported in some oral formulation users Sleep disruption or irritability potential sign of overstimulation Theoretical safety concerns Critical note: Because Dihexa activates the HGF/c-Met pathway which promotes cellular growth and repair there is a theoretical concern that it could potentially stimulate unwanted cell proliferation in individuals with active cancer or high cancer risk
These FDA-approved (Food and Drug Administration) brand-name medications, such as Ozempic, Wegovy, and Rybelsus, belong to the GLP-1 receptor agonist class
PMID: 8950613
In conclusion, we found that prescription of SGLT2 inhibitors and GLP-1 RAs could be increased substantially with a clinical-level population health intervention and that evaluation could be performed using easy-to-obtain data from existing clinical reports
JAMA 2009
US$ 21.08
US$ 29.01
US$ 23.62
US$ 20.68
